Pavel is an MRC Investigator (Programme Leader Track) and NIHR Fellow working on the development and implementation of adaptive designs in clinical trials. He provides statistical support in a number of academic clinical trials and consults pharmaceutical companies on the development of novel adaptive designs and supports their implementations in real trials.

Dr. Gina D’Angelo is a Director at AstraZeneca Oncology Statistical Innovation, and offers her guidance and statistical expertise on early-late clinical trials. She has over 20 years of academic and industry experience on preclinical and clinical trials with an emphasis on dose-finding, biomarkers, and study design. She received a PhD in Biostatistics from University of Pittsburgh and was faculty in the Biostatistics Division at Washington University in St. Louis. She is co-authoring a book chapter on dose optimization and co-editing a book on statistical and design consideration for biomarkers in clinical trials. Her experience spans from discovery to late phase trials, with small to high-dimensional data, across various therapeutic areas.

Dr. Michael Sweeting is the Director of Statistical Innovation in Oncology Biometrics at AstraZeneca, with over two decades of extensive research and management experience in Biostatistics. His expertise spans early and late-phase trial design, real-world evidence (RWE), observational data analysis, Health Technology Assessment (HTA), simulation, and software development. Michael is dedicated to advancing innovative statistical research and leadership within drug development and reimbursement and is committed to creating tools and training materials to facilitate the implementation of new statistical methods.
Before joining AstraZeneca, Michael served as an Associate Professor at the University of Leicester and a Senior Researcher at the University of Cambridge. There, he was the lead statistician on several high-profile cancer and cardiovascular research programs. He has published in both substantive and methodological areas of research, with an h-index of 64, over 250 peer-reviewed publications, and more than 15,000 citations.